AnaptysBio holds the No. 137 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis EXEL, TG Therapeutics TGTX and Harmony Biosciences HRMY are among the top 5 highly rated stocks ...

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

J.P. Morgan analyst Anupam Rama maintained a Buy rating on AnaptysBio today and set a price target of $80.00. The company’s shares opened today at $28.15. Take advantage of TipRanks Premium at 50% off ...

AnaptysBio (ANAB) stock market value increased 16.42% since last Buy rating. Financial partnership with GSK bodes favorably with hopes for added growth. Read more here.

Ratings for AnaptysBio (NASDAQ:ANAB) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.Summarizing their recent assessments, the table ...

What happenedShares of clinical-stage biotech AnaptysBio (NASDAQ: ANAB) were rising sharply on Tuesday following bullish commentary from a Wall Street analyst. The company's stock was up by 5.6% ...

AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ‘highest ever’ responses at week 14, with 69% of patients achieving ...

AnaptysBio, Inc. (ANAB) shares rallied 30.5% in the last trading session to close at $16.15. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

AnaptysBio, Inc. Initiated a global Phase 2b trial to treat atopic dermatitis with ANB032, a BTLA agonist. Hosting a virtual BTLA Agonist (ANB032) R&D Event on May 25, 2023.

TD Cowen analyst Joseph Thome has maintained their bullish stance on ANAB stock, giving a Buy rating today. Joseph Thome’s rating is based on several compelling factors. Despite AnaptysBio ...